(2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-5-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:152308

Synonyms

alpha-D-gluco-hexopyranosyl-(1->3)-alpha-D-gluco-hexopyranosyl-(1->2)-[alpha-D-gluco-hexopyranosyl-(1->6)]-D-gluco-hexopyranose
Glc(a1-3)Glc(a1-2)[Glc(a1-6)]Glc
WURCS=2.0/2,4,3/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2/a2-b1_a6-d1_b3-c1

Definition

References

GlyGen:G58522OL
GlyTouCan:G58522OL

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-5-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-5-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-5-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-5-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model